split-banner-image

REPURPOSING A COMMON REFLUX DRUG TO EASE CHEMOTHERAPY NAUSEA

The PantoCIN study was a Discretionary Funding Project in New Zealand.

As if coping with a breast cancer diagnosis and treatment isn’t enough, some patients are then plagued by nausea that lasts for days, well past the point at which chemotherapy drugs are out of their system.

It’s distressing both for patients and the clinicians committed to making them more comfortable. Medical oncologist Dr Navin Wewala says fear of side effects is so significant for some patients that it makes them consider omitting potentially life-saving treatment.

While drugs are available to manage nausea during chemotherapy, the incidence of delayed chemotherapy-induced nausea and vomiting (CINV) remains high, affecting more than half of all patients.

Starting with the hypothesis that chemotherapy and steroids change the gastric environment and irritate the stomach lining, Dr Wewala and Dr Richard Isaacs collaborated with Cancer Trials New Zealand to run a clinical trial testing whether Pantoprazole, a commonly used medication for treating gastric reflux and heartburn, could ease post-chemotherapy nausea.

Pantoprazole is a proton pump inhibitor, in a class of drugs that work by reducing production of stomach acid. Dr Wewala says some oncologists have been prescribing the drug for patients who report that it reduces symptoms, but a clinical trial was an important step in proving its effectiveness.

“The drug is very safe, but we also needed to know that benefits outweigh risks. We don’t want to give it to everyone without proving that it works and is safe in this specific situation.

“And even though some clinicians believed in it and liked using it, there were others who didn’t think it was helpful.”

The PantoCIN study, conducted from 2019 to 2021, involved 160 patients from 10 cancer centres across New Zealand, with all participants trialling both the medication and a placebo. This was a discretionary funding projects supported by our generous donors to Breast Cancer Trials.

Dr Wewala says the results were encouraging, indicating Pantoprazole completely alleviated delayed CINV for one in every eight people, and that the overall group reported reduced nausea.

“When you tackle the subject of reducing nausea, you have the potential to improve people’s more general health while they’re managing cancer,” he says.

The results will give clinicians more certainty and boost confidence in prescribing Pantoprazole to reduce nausea.

“If we have drugs that can help, that are already available and affordable, and are proven to be safe and well tolerated, then it’s a shame not to establish that they’ve got another use.”

Publication:

Navin Wewala, Katrina Sharples, Yujin Kim, Sarah Benge, Robert Cartwright, Louise Clement, Ying Huang, Richard Isaacs. PantoCIN: Pantoprazole’s effectiveness as prophylaxis against delayed Chemotherapy-Induced Nausea and Vomiting (CINV) in patients receiving adjuvant or neoadjuvant breast cancer chemotherapy [abstract]. In: Proceedings of the 2022 San Antonio Breast Cancer Symposium; 2022 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2023;83(5 Suppl):Abstract nr PD8-01 https://doi.org/10.1158/1538-7445.SABCS22-PD8-01

 

 

Support Us

Help us to change lives through breast cancer clinical trials research

Latest Articles

the village effect: why community matters during breast cancer treatment
routine, resilience and research: one mum’s cancer story
split-banner-image

OLAPARIB INCREASES SURVIVAL FOR EARLY BREAST CANCER PATIENTS WITH BRCA1/2 GENE MUTATIONS

Results from a global clinical trial have shown a 32% reduction in breast cancer deaths in patients where the cancer had not spread beyond the breast or under the arm.

The OlympiA trial has revealed practice changing results, demonstrating a significant improvement in survival for patients with early breast cancer who carry BRCA1 or BRCA2 gene mutations.

The study, led in Australia by Professor Kelly-Anne Phillips, focused on the use of the targeted drug olaparib as additional therapy for patients with high-risk, early-stage breast cancer and BRCA1/2 gene mutations.

The trial included 1,836 participants with BRCA1 or BRCA2 mutations from around the world, including 60 women from Australia, and examined the effectiveness and safety of olaparib compared to a placebo. Patients received either olaparib or a placebo after undergoing chemotherapy, surgery and radiation therapy when needed.

Additionally, hormone therapy was given alongside the study medication for hormone receptor-positive cancers. The study found that olaparib, taken twice daily for a year, improved overall survival rates and was generally well-tolerated by patients.

“Approximately 5% of patients diagnosed with breast cancer have an underlying inherited BRCA1 or BRCA2 gene mutation,” explains Professor Phillips, highlighting the importance of the results. “This equates to roughly 1,000 [of the] women in Australia each year [who are] diagnosed with breast cancer. Typically, these women are diagnosed with breast cancer at a young age and may have a more aggressive form of the disease.”

Olaparib works by targeting a specific weakness in the cancers of people with BRCA1 or BRCA2 mutations, making cancer cells more likely to die when treated with the drug.

With an average follow-up period of 3.5 years, the OlympiA trial showed a 32% reduction in breast cancer deaths in patients whose cancer had not spread beyond the breast or local lymph nodes. The four-year overall survival rate was 89.8% in the olaparib group compared to 86.4% in the placebo group, and no new safety concerns were identified.

These findings emphasise the importance of genetic testing for inherited BRCA1 and BRCA2 abnormalities in women with breast cancer to determine if they might benefit from this new treatment. Professor Phillips expressed her gratitude to trial participants and participating institutions, recognising the “significant and practice-changing results that provide a new treatment option for these patients”.

Publication:

Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer.

Geyer CE Jr, Garber JE, Gelber RD, et al. Ann Oncol. 2022 Dec;33(12):1250-1268. Epub 2022 Oct 10. PMID: 36228963. Doi: 10.1016/j.annonc.2022.09.159.

 

Support Us

Help us to change lives through breast cancer clinical trials research

profile image

Professor Kelly-Anne Phillips

The Breast Cancer Trials Study Chair of the OlympiA clinical trial, Professor Kelly-Anne Phillips.

Learn about BRCA-P Clinical Trial

BRCA-P is a world-first trial that aims to prevent breast cancer in women with a BRCA1 gene mutation.

Latest Articles

brca1 & brca2 gene mutations
solace – a clinical trial for breast and ovarian cancer
dimity paul – brca1, clinical trials & supportive communities
improving recruitment to a world-first trial
split-banner-image

NEW OPTIONS FOR TRIPLE NEGATIVE BREAST CANCER PATIENTS

Promising early results for the CHARIOT clinical trial.

Researchers are seeking additional treatments for early-stage triple negative breast cancer (TNBC) when standard chemotherapy proves ineffective.

Conducted by Breast Cancer Trials researchers in Australia, the CHARIOT clinical trial evaluated the effectiveness of two immunotherapy drugs, nivolumab and ipilimumab, combined with standard chemotherapy in treating TNBC. The study enrolled 34 patients with newly diagnosed stage-3 TNBC who had a suboptimal response to initial anthracycline-based chemotherapy. These patients then received nivolumab and ipilimumab with paclitaxel chemotherapy prior to surgery. The results, presented at the American Society of Clinical Oncology (ASCO) international conference, show promise in this uphill battle.

TNBC is a breast cancer subtype with the poorest prognosis, as it is more likely to spread within the body and can be less sensitive to chemotherapy than other subtypes. For patients who still have evidence of cancer after receiving chemotherapy and before surgery, the risk of relapse and death within three years is concerningly high.

The CHARIOT clinical trial aimed to determine if adding immunotherapy drugs to standard chemotherapy could safely and effectively stimulate the body’s immune system to kill cancer cells and eradicate residual cancer cells. The results were encouraging: 24% of participants experienced a complete disappearance of cancer within the breast and lymph nodes by the time of surgery. These results were regardless of the patients’ varying levels of PD-L1, a specific protein that can affect how well they respond to immunotherapy.

Although the treatment came with expected side effects, these were manageable. The most common immune-related event was low-grade pneumonitis (lung inflammation), which occurred in 27% of patients and typically resolved promptly with appropriate treatment.

Professor Sherene Loi, the study chair of the CHARIOT clinical trial, celebrated the results but acknowledged more research is needed. “While we have seen some promising results in the pathological response rate of this treatment, the survival benefits of adding ipilimumab to treatment is currently unclear,” she says, adding that the study will now follow up with patients to determine event-free survival (EFS) and overall survival (OS).

Publication:

Loi, S., Francis, P. A., Zdenkowski, N., Gebski, V., Fox, S. B., White, M., Kiely, B. E., Woodward, N. E., Hui, R., Redfern, A. D., Calvert, R., Rennie, L., Boyle, F. M., & Breast Cancer Trials-Australia and New Zealand (2022). Neoadjuvant ipilimumab and nivolumab in combination with paclitaxel following anthracycline-based chemotherapy in patients with treatment-resistant early-stage triple-negative breast cancer (TNBC): A single-arm phase 2 trial. Journal of Clinical Oncology, 40(16_suppl), 602-602. Published online June 2, 2022.

Support Us

Help us to change lives through breast cancer clinical trials research

profile image

Professor Sherene Loi

Study Chair of the CHARIOT clinical trial and Board Director Professor Sherene Loi.
See More

Latest Articles

the village effect: why community matters during breast cancer treatment
routine, resilience and research: one mum’s cancer story
split-banner-image

BREAST MRI MAY ALLOW SOME PATIENTS TO SAFELY AVOID RADIATION THERAPY

Primary results of the PROSPECT clinical trial.

The PROSPECT clinical trial has revealed promising results, offering a new perspective on the role of preoperative magnetic resonance imaging (MRI) in breast cancer treatment. The results of the study, conducted by Breast Cancer Trials in Australia, suggest that MRI scans could help identify early-stage breast cancer patients treated with wide local excision who can safely forego radiation therapy. The findings were presented at the American Society of Clinical Oncology (ASCO) international conference.

This trial challenges the current standard treatment protocol for selected early breast cancer patients. Currently, most women undergo radiotherapy after a wide local excision (or lumpectomy or partial mastectomy) to treat any remaining cancer cells in the breast and minimise the chances of local recurrence. However, the PROSPECT trial aimed to evaluate whether MRI scans could effectively select women who don’t require radiotherapy due to an already low risk of cancer recurrence within the breast.

The trial’s hypothesis centred on the idea that many recurrences seen after wide excision without radiotherapy might be due to hidden ‘occult’ cancers. These occult cancers could be detected by MRI but not standard mammogram or ultrasound imaging. Consequently, patients with a clear MRI, showing no additional disease, might be able to safely avoid radiotherapy – and its associated side effects, inconvenience and costs.

Between September 2011 and May 2019, the trial screened 443 patients and radiotherapy was omitted in 201 of them. MRI scans discovered additional cancers or pre-cancerous areas in 11% of patients, who received usual treatment. A total of 242 participants were not able to have radiotherapy omitted as part of the trial due to factors including occult lesions, breast characteristics or tumour characteristics. After a median follow-up period of five years, the local recurrence rate for those who didn’t undergo radiotherapy was an impressively low 1%. The entire cohort also had a very low recurrence rate, suggesting that identifying and treating all cancerous areas is important in preventing cancer recurrence.

Highlighting the significance of the trial, PROSPECT study chair Professor Bruce Mann explained researchers are currently developing a follow-up trial to confirm the initial findings. “We are hopeful this will pave the way for many of those diagnosed with early low-risk cancer to safely receive less intense treatment with less physical and psychological impact, while maintaining a very low risk of cancer recurrence,” he says.

Publication:

Mann, B., Rose, A., Hughes, J., Skandarajah, A., Murugasu, A., Spillane, A., Chua, B., Zdenkowski, N., Badger, H., Braggett, H., Gebski, V., Eggins, R., Park, A., Collins, J., & Breast Cancer Trials. (2022). Primary results of ANZ 1002: Post-operative Radiotherapy Omission in Selected Patients with Early Breast Cancer Trial (PROSPECT) following pre-operative breast MRI. Journal of Clinical Oncology, 40(16_suppl), 572-572. https://doi.org/10.1200/JCO.2022.40.16_suppl.572

Support Us

Help us to change lives through breast cancer clinical trials research

profile image

Professor Bruce Mann

Study Chair of PROSPECT and Director of Research at Breast Cancer Trials – Professor Bruce Mann.

Latest Articles

the village effect: why community matters during breast cancer treatment
routine, resilience and research: one mum’s cancer story
split-banner-image

BLOCKING CELL DIVISION HELPS WITH BREAST CANCER RELAPSE IN OLDER WOMEN

Research to treat metastatic relapse of the most common form of breast cancer in post-menopausal women.

Results after seven years follow up of the international PALOMA-2 trial have shown that the cyclin dependent kinase inhibitor palbociclib (Ibrance) used in conjunction with endocrine therapy, letrozole, to treat metastatic relapse of the most common form of breast cancer in post-menopausal women did not improve overall survival when compared with letrozole therapy alone. Whilst there was a numerical 2 month difference, it did not meet a predefined level of statistical significance.

Treatment using both palbociclib and letrozole has already been reported to nearly double progression-free survival in these women from a median 14.5 months to 27.6 months. At the American Society of Clinical Oncology Annual Meeting in Chicago last June, PALOMA-2 study researchers reported overall survival was 51.2 months with letrozole alone and 53.9 months using the dual therapy.

PALOMA-2 was the first trial to look at the impact of adding a cyclin-dependent kinase (CDK) inhibitor (palbociclib) to the standard treatment of an endocrine inhibitor (letrozole) in post-menopausal women with oestrogen receptor positive breast cancer that had relapsed as advanced or metastatic disease. The study enrolled 666 women, including 20 in Australia and New Zealand.

There are likely to be several reasons for the lack of statistical significance of the result, says medical oncologist Dr Janine Lombard of the Calvary Mater Newcastle Hospital.

As the Breast Cancer Trials (Australia New Zealand) principal investigator for the international study, Dr Lombard says missing data was a major concern.

“Unfortunately, by the time of the survival analysis, one-third of the patients were lost to follow-up. We don’t know what happened to them. But it meant that our statistics were not powerful enough to show a difference in survival,” she says. In the 10 years since the trial completed, however, two other drugs similar to palbociclib have come on the market, one of which improves overall survival in a very similar group of women with advanced hormone positive breast cancer, with the survival analysis of the other drug still pending.

“Palbociclib really does make a difference, however,” says Dr Lombard. “It doubles the time of cancer control, allowing more time for women needing to navigate to another therapy because the cancer has progressed. And it is very, very well tolerated, because it is not a chemotherapy. You don’t have any of the chemo toxicity, the hair loss and vomiting. In fact, for most women, the side effect profile is very favourable.”

Similar studies to PALOMA-2 have been undertaken with two other CDK inhibitors. Dr Lombard says the results mirror what has been found with Palbociclib and all significantly increase progression free survival.

These drugs all have slightly different side-effect profiles, which means if patients can’t tolerate one, there is now the confidence to switch to one of the others. “It is always good for patients if you have more than one tablet option.”

Publication:

Richard Finn, Hope Rugo, Veronique Dieras, Nadia Harbeck, Seock-Ah Im, Karen Gelmon, Janice Walshe, Miguel Martin, Mariana MacGregor, Eustratius Bananis, Eric Gauthier, Dongrui Lu, Sindy Kim and Dennis Slamon (2022) Overall survival (OS) with first-line palbociclib plus letrozole (PAL+LET) versus placebo plus letrozole (PBO+LET) in women with estrogen receptor–positive/human epidermal growth factor receptor 2–negative advanced breast cancer (ER+/HER2−ABC): Analyses from PALOMA-2. Oral Abstract for American Society of Clinical Oncology meeting, Chicago https://ascopubs.org/doi/abs/10.1200/JCO.2022.40.17_suppl.LBA1003

 

Support Us

Help us to change lives through breast cancer clinical trials research

profile image

Dr Janine Lombard

The Breast Cancer Trials principal investigator for the international PALOMA-2 study, Dr Janine Lombard.

Latest Articles

the village effect: why community matters during breast cancer treatment
routine, resilience and research: one mum’s cancer story
split-banner-image

ASSESSING THE EFFECT OF BREAST CANCER TREATMENT ON OVARIAN FUNCTION

In this BCT Discretionary Funding Project, researchers explored the benefits of collecting data on ovarian toxicity during clinical trials research.

New clinical trials of breast cancer treatments may be more likely to assess those treatment’s impact on ovarian function, as a result of recent research looking at why such information isn’t commonly collected in clinical trials.

Even though it is well known that chemotherapy used for the treatment of breast cancer can reduce the function and lifespan of the ovaries, the recent research surprisingly showed the main reason data on ovarian toxicity wasn’t collected in breast cancer trials was simply that “it wasn’t considered” during trial design.

“That’s quite a disconnect with what we do in clinical practice,” says lead author of the study Dr Wanda Cui, who is a medical oncologist at the Peter MacCallum Cancer Centre in Melbourne. “Young women who are premenopausal have stated that fertility issues and early menopause are critical factors in their decision making about treatment options. Studies have shown women would change their treatment decisions if one regimen was more likely to lead to impaired fertility compared to another with similar efficacy [against the cancer].”

In the study, 25 people across 14 countries were interviewed. They included clinicians, consumers, members of regulatory agencies and pharmaceutical company representatives. This study received discretionary funding support from Breast Cancer Trials, thanks to the generosity of our supporters.

One of the clinicians who participated in this research said the lack of ovarian toxicity assessment in clinical trials was “a failure of the entire research world”. As well as fertility issues, ovarian toxicity can have profound impacts on long-term bone density, cardiovascular health and cognitive function.

Dr Cui says other reasons the participants listed for not assessing treatment-related ovarian toxicity in clinical trials was the pressure on trial resources in such studies, and also that information on ovarian toxicity wasn’t currently required for regulatory drug approval. In addition, some mentioned they weren’t sure how to collect or interpret such data.

But many participants acknowledged preservation of ovarian function was fundamental to a woman’s quality of life.

“Decades ago, often the only aim of breast cancer treatment was to keep people alive,” Dr Cui says. “Now there’s been a shift. Although keeping them alive is still fundamental, there’s much more emphasis on survivorship – what’s life like after cancer?”

She says that as a result of the research, there is now more interest from international oncology groups as to how to collect data on ovarian toxicity during treatment trials. “We’ve already started to see more of a conversation and a bit more interest in looking at these data in clinical trials.”

Publication:

Wanyuan Cui, Kelly-Anne Phillips, Prudence A. Francis, Richard A. Anderson, Ann H. Partridge, Sherene Loi, Sibylle Loibl, Louise Keogh. Understanding the barriers to, and facilitators of, ovarian toxicity assessment in breast cancer clinical trials. The Breast. 2022; 64: 56–62. https://doi.org/10.1016/j.breast.2022.05.002

Support Us

Help us to change lives through breast cancer clinical trials research

profile image

Dr Wanda Cui

Dr Wanda Cui received Discretionary Funding thanks to the generosity of our supporters to conduct this research.

Latest Articles

the village effect: why community matters during breast cancer treatment
routine, resilience and research: one mum’s cancer story
split-banner-image

2022 SAN ANTONIO BREAST CANCER SYMPOSIUM

A summary of key announcements and research developments presented at SABCS 2022.

2022 San Antonio Breast Cancer Symposium (SABCS)

The San Antonio Breast Cancer Symposium (SABCS) is one of the largest breast cancer conferences in the world, that brings together researchers to hear the latest developments which help to guide patient care.

This is an international conference directed primarily towards academic and private physicians and researchers involved in breast cancer in medical, surgical, gynaecological and radiation oncology, as well as patient advocates and health care professionals.

The 2022 conference attracted more than 8,000 attendees from more than 80 countries, including researchers from Breast Cancer Trials.

We have provided a summary of important results presented at SABCS 2022 below:

MonarchE: Overall Survival and Disease-Free Survival

Previous research has shown that treatment with abemaciclib after surgery reduces the risk of breast cancer recurrence. Adjuvant abemaciclib plus endocrine therapy (tamoxifen or an aromatase inhibitor), significantly improves invasive disease-free survival and distant relapse-free survival in patients with hormone receptor positive, HER2 negative, high-risk early breast cancer.

This analysis with longer follow-up confirms that the benefit of abemaciclib is sustained beyond the completion of treatment with an absolute increase in invasive disease-free survival at 4 years, further supporting the use of abemaciclib in patients with high-risk hormone receptor-positive, HER2-negative early breast cancer. Almost all patients had completed their study treatment, remaining on standard of care endocrine therapy. An interim analysis of overall survival in the phase III monarchE clinical trial, has shown no significant benefit with the addition of adjuvant abemaciclib to endocrine therapy, however the survival results are early. 5,637 patients participated in this trial from 38 countries.

Further follow-up is needed to establish whether overall survival can be improved with abemaciclib plus endocrine therapy in these patients.

DESTINY-Breast03

Trastuzumab emtansine is the current standard treatment for patients with HER2-positive metastatic breast cancer, whose disease has progressed after treatment with a combination of anti-HER2 antibodies and a taxane.

The aim of the DESTINY-Breast03 trial was to compare the efficacy and safety of trastuzumab deruxtecan versus trastuzumab emtansine, in patients with HER2-positive metastatic breast cancer. This randomised phase III international trial was conducted in North America, Asia, Europe, Australia and South America, with 524 patients.

The first interim analysis of the study was met with much enthusiasm when presented previously, founding that the risk of disease progression or death was substantially lower among those who received trastuzumab deruxtecan, than those who received trastuzumab emtansine. The duration of progression-free survival (amount of time that patients on the study remained alive and without evidence of worsening cancer), as assessed by blinded independent central review, was significantly longer with trastuzumab deruxtecan (29 months) than with trastuzumab emtansine (7 months).

This presentation reported on the prolongation of overall survival in patients on trastuzumab deruxtecan. Overall survival is widely considered the gold standard in measuring the benefits of new cancer treatment strategies. Patients on trastuzumab deruxtecan had a 36% lower chance of dying compared with trastuzumab emtansine. These are practice changing results in the treatment of metastatic disease and a major step forward for patients.

The POSITIVE Trial

While most breast cancers are diagnosed in people who are aged over 40, younger patients may face unique challenges when diagnosed with breast cancer including the impact on fertility.

Young patients with early-stage hormone receptor-positive breast cancer are often treated with endocrine therapy, such as ovarian function suppression, aromatase inhibitors, or tamoxifen.

The POSITIVE clinical trial examined whether pausing endocrine treatment was safe in patients who wanted to become pregnant. 518 patients participated in the study, all of whom were under the age of 43, and patients opted to pause endocrine therapy for up to 2 years to try to become pregnant, following the completion of 18 to 30 months of adjuvant endocrine therapy.

Patients with breast cancer who paused their endocrine therapy while attempting to conceive, experienced rates of breast cancer recurrence similar to patients with breast cancer who did not pause their therapy for pregnancy and many of them went on to conceive and deliver healthy babies. This is reassuring for the many premenopausal patients diagnosed with breast cancer who are considering pregnancy. Researchers plan to continue following study participants to assess recurrence risk over a longer timeframe.

This research was led by Professor Ann Partridge, Professor of Medicine at Harvard Medical School and Vice Chair of Medical Oncology at the Dana-Farber Cancer Institute, who was a guest speaker at the 2022 Breast Cancer Trials Annual Scientific Meeting (ASM). Watch her video interview at the ASM here.

The RIGHT Choice Study

Patients with metastatic breast cancer that is hormone receptor positive and HER2-negative may consider treatment with hormone-blocking (endocrine) therapy or chemotherapy. The prevailing understanding has been that those with tumours that appear faster growing or are threatening organ function, are more suited to chemotherapy. The advent of the CDK 4/6 inhibitors (palbociclib, ribociclib and abemaciclib) has resulted in significantly improved outcomes for patients with metastatic hormone receptor positive breast cancer and has challenged this assumption about treatment options.

The RIGHT Choice study aimed to compare the results of endocrine therapy versus chemotherapy as initial treatment of patients with metastatic cancer, that was deemed to be aggressive or high risk. The investigators found that patients actually appeared to do better with the endocrine therapy and ribociclib compared with chemotherapy. Cancers remained under control for longer, and the side effects were less with the endocrine therapy/CDK4/6 inhibitor treatment. These results are reassuring for clinicians and patients who are aiming for both cancer control and good quality of life.

Low Dose Tamoxifen in Non-Invasive Breast Cancer (DCIS)

Patients diagnosed with non-invasive breast lesions such as DCIS and lobular carcinoma in situ (LCIS), and atypical breast lesions such as atypical ductal hyperplasia (ADH) and atypical lobular hyperplasia (ALH), are at increased risk of developing invasive breast cancer. Treatment with tamoxifen, at 20mg daily for 5 years, has shown to be effective for preventing breast cancer in these at-risk patients but its use can be limited by its adverse effects.

The objective of the Tam01 study from Italy was to evaluate the use of low dose tamoxifen and determine how many patients preferred this option. 500 women who were 75 years of age or younger participated in the trial.

The study found that low dose tamoxifen (5mg daily for 3 years) in patients with DCIS, ALH, and ADH resulted in an approximate 50% risk reduction in breast cancer events compared to placebo, with a slight increase in hot flushes but no increases in uterine cancer or venous thromboembolism within the tamoxifen group. These side effects are uncommon, but known to occur in a small number of patients treated with the standard dose of 20mg tamoxifen. Overall, these 10-year data shows that low dose tamoxifen continues to reduce incidence of invasive breast cancer or DCIS. These results may help patients who have not had a diagnosis of invasive breast cancer and are candidates for tamoxifen for prevention but are concerned about the side effects of this medication.

HELP UNCOVER BETTER TREATMENT OPTIONS

Latest Articles

the village effect: why community matters during breast cancer treatment
routine, resilience and research: one mum’s cancer story
split-banner-image

DIANE BARKER – TRIPLE NEGATIVE BREAST CANCER & PARTICPATING IN A CLINICAL TRIAL

We spoke with Diane about her diagnosis, her decision to participate in a clinical trial, and the importance of supporting breast cancer clinical trials research.

Meet Diane

Diane Barker lives in Sydney with her husband Mike, their daughter Eva and their dog Boston. In December 2020, at just 44 years of age, Diane was diagnosed with locally advanced triple negative breast cancer.

“I’m a lawyer by training and work in a university. I’ve got a husband and a little girl, she’s almost nine, and a dog who’s been a therapy dog for me over the last couple of years. I live in Sydney’s inner West. I’ve always lived in Sydney.”

“I’ve got a large family, so I’ve still got my dad. My mum passed away about 13 years ago from brain cancer, but I’ve still got my dad and seven brothers and sisters. So, I’ve actually got a PhD in archaeology, so that’s sort of my side hustle. I really love that, and I’ve done a lot of work in the Middle East, so lots of travel over there.”

“I love gardening, I love going riding with my family. My husband started mountain biking, not long before I got sick, and I recently started taking it up because my balance was really badly affected by all of the treatment that I had. So, riding a mountain bike, It’s a real challenge for me but lots of fun.”

“I love traveling, I haven’t been able to do a lot of that in the last couple of years for multiple reasons, but I’m very excited to be going overseas early next year, which will be great. I love spending time with my family in particular. They’ve been amazing through all of this. My husband, my daughter, but also my brothers and sisters and, and my dad as well.”

“So, I’ve got simple needs. I don’t have an extravagant lifestyle, but I just really appreciate what I’ve got at the moment, especially now that I’ve gone through the cancer treatment experience.”

Listen to the Podcast

In December 2020, at just 44 years of age, Diane was diagnosed with locally advanced triple negative breast cancer. We spoke with Diane about her diagnosis, her decision to participate in a clinical trial, and the importance of supporting breast cancer clinical trials research.

Being Diagnosed with Triple Negative Breast Cancer

“So, I do remember feeling incredibly tired, like more tired than I had ever felt in my entire life. And yes, I’ve got a busy job, but I just thought maybe something was going on. And actually, my GP and I were about to start a process of, you know, a sleep clinic and doing a sleep study to see what was happening.”

“But I was also, going through a process of having regular mammograms and ultrasounds, because my mum had had breast cancer when she was 59. So, when I turned 40, my GP said we should start doing this for you. So, I’d been doing that for a few years, and everything was fine.”

“I went to my regular scan and that process with the mammogram and the ultrasound and some red flags started appearing. I thought that maybe something might be going on when the technician called the radiographer into the room to have a look herself and I could just see the look of concern that she couldn’t entirely mask on her face. I had to go back for a biopsy, which is when I started to really think that maybe something serious was going on.”

“Then when I got the result from my GP, I was in the middle of a meeting at work and she said, I’m afraid it’s cancer. That was when everything changed for me. It was quite shocking. I was preparing myself for that news, but really nothing can prepare you for news like that. It’s devastating. It’s absolutely devastating.”

“I didn’t know at the time how bad it was and whether I would live or die. There were so many unknowns at that point and it was terrifying. I do remember the first week between when I got the diagnosis, and when I got the final scan done, which demonstrated that the cancer hadn’t spread throughout my body, that week was the most horrifying week I’d ever lived.”

“It was completely uncertain. I knew it had spread to my lymph nodes, but I didn’t know if it had spread anywhere else in my body. So, I didn’t know if it had metastasized. I was terrified, I couldn’t sleep. I had all of my family and my friends around me, but it was such a lonely place. I was the only one who could live this, who could process it, who could really deal with it. And it was lonely.”

“I remember thinking, I knew exactly how my mum felt when she was dying of cancer. It was an awful experience. On the Wednesday after I was diagnosed, I got a call from my medical oncologist with the PET scan results, which I’d had that morning, and he confirmed that it hadn’t spread throughout my body.”

“There was no metastatic cancer. It was stage three, but it was limited to my lymph nodes. And I just remember this enormous sense of relief. I moved from a space of living in fear to living in hope because I thought, okay, there are things that can be done for me. So that’s when all the treatment started.”

“I’d noticed before my regular scan in 2020, that there was a bit of swelling in my right breast. I wasn’t too concerned about it. You know, I didn’t really know what was going on, but I wasn’t too concerned about it because my previous scan the previous year was completely fine, so I wasn’t too worried.”

Receiving Breast Cancer Treatment

“In hindsight, we put our lives on hold for about two years. We were living in limbo. We were living from day to day and from result to result, treatment to treatment, scan to scan. There was a lot of that. I just had to get through every day during the treatment, the chemotherapy. I was very sick, so some days it was really hard getting out of bed.”

“I still worked throughout the whole process, which in hindsight, I don’t know how I did it, but I did it. I wanted to concentrate on something other than my cancer and I didn’t want the cancer to define me. So, I did work throughout the whole period.”

“My medical oncologist said most people don’t do what you do, but I felt it was important to keep going but at the same time it was really hard. It was a real struggle sometimes to do even the normal activities of daily living. Some days I’d get home from work and I would just collapse into bed.”

“I couldn’t put my daughter to bed. I couldn’t read her a story. I couldn’t eat dinner with the family, couldn’t take the dog for a walk. That there were so many things, so many little things that I missed during that period. It was such a haze of treatment. And I knew, I’d have my treatment on a Monday and I usually feel pretty good on the Monday. But I knew that by the Tuesday morning I’d be feeling pretty low, and it would worsen over a few days and then I would start to come out of it. And that was for the first 12 weeks.”

“The second lot of 12-week chemotherapy infusions were even worse. I had chemotherapy every three weeks. One of the drugs I was infused with is colloquially called the Red Dragon or the Red Devil. It’s this horrible looking pouch of red fluid that gets pumped into you.”

“It’s so toxic that the chemotherapy nurse had to sit by my side the whole time. The protocol was that they weren’t allowed to leave the patient’s side because it was so toxic and there was such a high risk of things going wrong with that drug.”

“So that drug made me feel really, really terrible for about a week and a half after the infusion, and then I’d have about a week and a half where I’d feel okay, and then I’d start the whole process again. So, it was difficult managing all of that, but my family were fantastic. Really great.”

“So, after I finished chemotherapy, I had a short break, but I’d had a scan towards the end of the chemotherapy infusions and it showed that one of my lymph nodes was starting to enlarge again. That caused my specialist’s a degree of concern. So, I saw my surgeon and she said that she wanted to get me into surgery straight away.”

“We were no longer looking at just a lumpectomy. We were looking at a mastectomy of the right breast. That was confronting for me because I was thinking the whole time that the chemotherapy is going to work wonders. I’ve got an aggressive form of triple negative breast cancer, but chemotherapy can work well with aggressive cancers.”

“So, I wasn’t expecting a mastectomy and that certainly had never been the end point for us. We were hoping that it would just be a lumpectomy, so it was quite shocking, but I had to deal with that. And then I realized that it would be better if I just got rid of the cancer. Take the breast off, get rid of the cancer.”

“So, I was pretty scared coming into the surgery. But when I woke up from the surgery and it had been completed, I realized that this actually could be the day that I was cured of cancer forever. My surgeon took all of the breast tissue up to the skin line, there was nothing left. She took 10 lymph nodes out as well.”

“She took everything she could, everything she possibly could, and I felt relieved that she did. I felt an incredible sense of relief. I recovered well from the surgery, and then I spent six weeks recovering from that but really, I bounced back pretty well after a few weeks. Then I went into five weeks of radiotherapy, which I thought was going to be tough, but was actually pretty straightforward for me.”

“I’d been exercising a lot, so I felt good. I didn’t have a lot of fatigue, which is one of the main side effects. My skin coped really well with it, so at the end of five weeks of radiotherapy, I felt great. It was also good because it was during lockdown and I had a reasonable excuse to leave the house every day.”

“I’m feeling hopeful, but it is a worry that I carry with me. It’s a burden that I carry with me and I think I will for the rest of my life. So, I just need to appreciate what I’ve got now and try and live life to the fullest. It sounds like a complete cliche, but it actually is very true. When you come from a point where you think you might die, being okay and getting through cancer, it really does change your perspective.”

“So, I was able to drive over to the hospital and I’d get a coffee, it was a good time. I felt really positive. And then after I finished radiotherapy, I was put on oral chemotherapy because the pathology results from my surgery were not good. I had a residual cancer burden score of three, which in medical terms is pretty bad.”

“So, my medical oncologist wanted me to go on oral chemotherapy. I couldn’t get onto it quickly enough, so we started it pretty immediately after I finished radiotherapy. But then because my immune system had been so badly affected by the radiotherapy, I didn’t know that at the time I had a terrible case of shingles, which almost hospitalized me.”

“I was so unwell. That was probably the worst part out of everything because it was just so painful. I’m still suffering some nerve damage from that, but in the scheme of things it’s completely manageable and I’m alive and it’s fine. So, once I recovered from that, I went on oral chemotherapy for six months and that was also fine.”

“We got the dosage right. I had a few issues with the skin on my hands and feet and I lost my fingerprints for a while. They still haven’t completely come back, but they’ll come back in time. And then that was the end of the treatment, six months of oral chemotherapy and then I stopped and then got a PET scan, which was completely clear and that was it.”

“So, it was pretty exciting to finish the treatment after everything I’d been through. I’d done every form of treatment I could, including immunotherapy for 12 months at the same time as the chemotherapy, and the surgery and the radiotherapy. It was also confronting at the same time because the safety blanket I’d had was no longer there, and I still live with the fear that the cancer will come back.”

“It’s a daily occurrence. Every time I look in the mirror, I see physically that I’ve changed. I used to have straight hair and when it grew back after the chemotherapy, it grew back curly like this. So, every time I look in the mirror, I’m reminded of the fact that I’m not the same person and that I’ve been through this experience.”

“It could come back at any time. I had an incredibly aggressive form of cancer. The risk of recurrence is really high during the first five years and I’m coming up to two years in December since my diagnosis, and that’s actually really good for my form of cancer.”

Learning About Triple Negative Breast Cancer

“So, I was pretty naïve about breast cancer before I was diagnosed. I had heard of hormone-related cancers. I don’t think I’d ever heard of triple negative breast cancer, to be honest. And so, when I was first diagnosed and the first specialist, I saw was my breast surgeon, Dr. Kylie Snook, she explained it to me.”

“I was a bit shocked because for whatever reason I had this perception in my mind that breast cancer was a really curable disease. You know, there’s been so much research and so much, attention paid to breast cancer fundraising over the years that I had this perception that things have come so far that this is going to be okay, this is not a problem at all. Breast cancer’s one of the most curable diseases that that we have now.”

“I had no reason to know about the different types of breast cancer and the different subtypes of breast cancer and the particular risks associated with any of them. I was completely in the dark, so to get the news that I had breast cancer for start, and that I had triple negative breast cancer, which is aggressive, which is highly deadly, which has a high recurrence rate, and which has very limited treatment options was an enormous shock and really.”

“It wasn’t what I was expecting when I first started to go through the medical treatment for my cancer. I avoided the temptation of playing Dr Google. I didn’t want to be in that space, so I simply asked a lot of questions of my treating professionals and they’ve all been fantastic.”

“All of them are so caring and empathetic and are so on the cutting edge of medical research that I felt really comfortable using them as my source of information, rather than trying to find things out for myself and working myself up into a state. So, I really trusted their advice and they’ve always given me really terrific advice.”

“But triple negative breast cancer is quite a difficult cancer. It’s often known as the young woman’s breast cancer because it’s not hormone related. I did go down the path of having genetic testing, which was recommended to me because there had been no evidence of triple negative breast cancer in my family.”

“Triple negative breast cancer had no indication in my family that I knew of, but because of my age and no other real risk factors, I was sent for genetic testing.”

“That was a really nervous wait, getting the results for that because I’ve got a daughter, she’s almost nine now, but at the time she was seven going on eight. I’ve also got four sisters and I was really worried for all of us. I was carrying this burden.”

“So, I got the results of the genetic testing and they were negative for any gene. BRCA1, BRCA2, the Angelina Jolie style of BRCA defect that people often hear about. So that was a relief in itself, but it means that no one knows what has caused my cancer, which is concerning in and of itself.”

“And so there needs to be more research into what causes triple negative breast cancer, because if we figure out what causes it, then there’s going to be more of an opportunity to do research into effective treatment. Because that’s the other thing with triple negative breast cancer – chemotherapy, radiotherapy, and surgery are fairly blunt tools when it comes to triple negative breast cancer and that’s why clinical trials are so important in this space.”

“My mum had had pre-breast cancer when she was 59, but it was completely different. She recovered from that very well.”

Participating in a Clinical Trial

“So, I first heard about Breast Cancer Trials as an organization through the ‘My Journey’ app. I had signed up to that and was going through various articles in the app one day and came across that, signed up and started getting information from the organization, which I found really interesting.”

“But at the same time when I had finished my treatment, my medical oncologist in his own mind, earmarked me as a potential candidate for a breast cancer trial. But I, at the same time, had been thinking that if there was any opportunity for me to give back in some way, I’d be more than happy to participate in a breast cancer trial as well.”

“So, when I finished my treatment and I got my final PET scan, which was negative and I suspected it was negative, but I didn’t know. I went to the appointment with him and when I saw the clinical trial coordinator in his room when I turned up for the appointment, I knew that I was okay because she wouldn’t have been there if the scan had shown any residual cancer.”

“So that was when I started to have the conversation with Associate Professor Menzies and the clinical trial coordinator about the trial that they were wanting to recommend me for. And we had a chat about that, and it involves a drug called Niraparib, which I understand is currently used for ovarian cancer patients and they’re trialing it for breast cancer patients.”

“It’s an international trial. They’re looking to recruit at least 10 individuals from Australia, and I’m going through St Vincent’s and Mater Health in Sydney. I’m actually still only in the screening process. So, there’s a whole process and part of the issue with treatments is they do take a long time to go from clinical trial statement status to market as well.”

“So, I’m being screened for that trial and every three months I get a special blood test, which is only used for clinical trials and it measures the level of circulating tumour DNA in my bloodstream. So, I’ve had three of those blood tests and I’m actually waiting on the third test result as we speak. The first two test results have been negative, which is amazing news for me. It means that there is absolutely no trace, no molecular trace of cancer in my body at all.”

“That could change. It doesn’t mean that it won’t ever happen. If it does change though, it does mean that I will go on the clinical trial immediately and it means that I’ll be able to offer something back to the system that has supported me so well.”

“One of the things that I think about often is the fact that I was given the opportunity to receive immunotherapy, which is one of the really amazing advances in cancer treatment in the last 10 or so years. It works very well for lung cancers and melanomas I understand. And they’re moving it across to other different types of cancer treatment. It’s still in a final stage clinical trial for breast cancer patients.”

“When I first saw my oncologist, I was referred to him precisely because he’s involved in clinical trials, including one involving immunotherapy. He was so confident in the ability of immunotherapy to help me, that he actually wanted me to be on that drug straight away rather than going through the final stages of this clinical trial process because he was so confident that the results were showing such good things for immunotherapy. So that’s why I ended up on immunotherapy for a year.”

“I did have to pay for it, and I was lucky that we were able to manage that because it’s a really expensive drug. It costs about $60,000 for that course of treatment. Most people don’t have access to that kind of money and it really breaks my heart. Whether you live or die or whether you have access to potentially lifesaving drugs, could depend upon how much you earn or what your resources are or how much support you have, you know, the access to medical treatment you might have.”

“It would be really great if that could change, and that’s why clinical trials are so important. We need people to participate in them so that there’s a greater chance of these drugs getting to market, sooner rather than later and hopefully getting on the PBS so that everyone can access them.”

A Message to Supporters

“So, supporters for Breast Cancer Trials are absolutely essential. They’re amazing people for giving time, money and effort to this particular cause.”

“For triple negative breast cancer patients, that sort of treatment was only possible because individuals had donated money to make research into that particular drug possible. That’s why I’m contributing, not only my own resources and I’m volunteering for a clinical trial myself, but I’m also a donor and very proud supporter of Breast Cancer Trials.”

“For that reason, I’ve been lucky that I’ve been able to access the amazing quality of care that I have. Not everyone has access to that and I feel like it’s incumbent upon me to give something back because I’ve had such a good experience. I was very well looked after and I’ve got a really good prognosis at the moment.”

“So, I’m coming up to two years since my diagnosis and I’m feeling probably better than I ever have. I’m fit, healthy, I’m well. I’m cancer free and I want it to stay that way, but I also want the assurance that should anything change in my condition in the future, that there are drugs available or treatments available that can potentially keep me alive and to keep me well for longer.”

“That’s only possible with clinical trials and the clinical trials are only possible if there is funding to make them happen.”

“In my own experience, during my treatment period I was given access to an immunotherapy drug and that was only possible because there were individuals who had gone through clinical trials with that drug, which meant that it was deemed clinically safe to be administered even before it had finished clinical trial testing.”

Receiving Support from Family and Friends

“I mentioned that I was really concerned when I was referred for genetic testing that I might be carrying a gene defect, which would mean that they would also be carrying the same gene defect. That was quite distressing to think that we might all end up in the same position. Thankfully, that wasn’t the case. But my family in general have been amazing supporters.”

“When I started losing my hair after the chemotherapy treatment started, three of my sisters shaved their heads for me, which was huge. It was absolutely amazing. They’ve been an incredible support to me and I don’t think I could have gotten through it without all of my family. It also meant that I was very, very firm with them about making sure that they themselves went straight to their GP’s and got referrals to get scans to make sure that they were okay.”

“I remember thinking at the time, I’m glad that I’m the one going through this, because I don’t want any of them to go through this. I love them too much. They’re too important for me. I’m the strong one, I can do this. And I did, I got through it. And I don’t want anyone else to go through it, even if doing this can save one person’s life, then it’s worth it because it’s the most awful traumatic and devastating thing to have to go through.”

“I certainly don’t want my sisters and especially my daughter to ever have to go through this. And in terms of my daughter, she’s almost nine. She’ll turn nine on New Years eve. I remember speaking to the genetic counsellor and the potential risks that my daughter might face if I was carrying one of the gene defects and I was really concerned about that.”

“Even before I had the results, she gave me a level of reassurance that notwithstanding that I might be carrying a gene defect myself, the chances that it would impact her in the same way as me, were less because it was likely that scientific developments would mean that the impact on her would probably be very different. Because we would know a whole lot more about those gene defects, we would know a whole lot more about the types of cancer that those gene defects would cause.”

“So, it made me look forward to a time where we can potentially treat these sorts of cancers much more easily with less side effects, less intervention, and with a great deal more hope than we might currently.”

“My husband has been my absolute rock throughout all of this. He’s done everything he can to help me physically and emotionally cope with the cancer. A couple of months before I was diagnosed, he took up mountain bike riding and he’s really into it. And when I was diagnosed, I still encouraged him to do that because he thought that he couldn’t do those sorts of things anymore. And I said, no, no, no, you need to keep doing that.”

“So, he gets up at 5am every Saturday and Sunday morning and goes off and rides for a couple of hours. It’s been fantastic for him and it’s been his way of meditating. So, when I was diagnosed, my husband and I spoke about how we were going to tell my daughter because we knew we would have to tell her.”

“We knew I was going to lose my hair and I’d be going to doctor’s appointments all the time. So, the fact that I was unwell was going to be pretty obvious to her. So, we got some help from her school counsellor. He gave us some resources, which were really helpful. There was one book in particular called ‘My Mum’s a Superhero’, that we sat down one Saturday morning, about two weeks after the diagnosis and we read it to her, and then we spoke about what was happening.”

That actually went a lot better than I expected. She didn’t want to ask a whole lot of questions at the time, but then we subsequently realized that what she was doing was internalizing a lot of it. So, we knew she was saying things to her friends at school and some of her teachers. I’d get messages of support from parents of the kids that she was playing with, and some of the teachers. A couple of the girls that she played with at school would ask me about the wig that I was wearing, and so we knew she was talking about it.”

“She’s very empathetic, so we were worried that she was not dealing with it well, and she did have a few episodes where she’d have panic attacks about dying, and that was linked to all of this. But she has come through it reasonably well.”

“One day, it wasn’t that long ago, I think it was after I got one of the PET scan results, she had been at after school care, and she made a beaded bracelet for me that said ‘MUMCF’, and I asked her what that meant and she said it means ‘mum’s cancer free’. So, she’s thinking about it. She’s pondering it.”

“She doesn’t always externalize it, but we are quite open with her about what’s going on. So, I took my daughter to one of my follow up appointments with my surgeon a couple of weeks ago, and it was the first time that she had seen the reconstruction and the scars, and she was okay with it.”

“We actually sat in the waiting room and she flicked through a coffee table book, which had been produced with really beautiful photographs of people who had gone through breast cancer treatment and who had mastectomies as well. And so, we used it as an opportunity to talk about what had happened to me. I said, well see this picture here, that’s what mummy looks like at the moment.”

“At first she was a little bit freaked out, but then when my surgeon explained what was going on and she gave her a breast implant to play with because kids love those fidget toys at the moment, she was fine about it and she actually thought it was pretty cool.”

“So, she’s taken it a lot better than I expected that she would. And my husband and I just take it one day at a time and we are there for her. We’re there for each other. I think that’s the main thing. It’s not been easy, but we do our best.”

Boston the Rescue Dog

“So, Boston is a rescue dog that we got during lockdown, so before I was diagnosed with cancer. He’s a cattle dog, cross staffy, cross greyhound, and a whole bunch of other things. I always knew dogs were amazing, but getting Boston made me realize how perceptive they are. So, there were some days when I was too sick to even get out of bed and he just laid at the end of the bed with me for the whole day and wouldn’t move.”

“He follows me around everywhere, one of my favourite things to do is take him for a walk. We love that time together. He’s been a great comfort for my daughter and for my husband as well, and he really is part of the family. There really is something I think in the idea of dog therapy. I really do believe in that.”

“Dogs are incredibly perceptive animals and he really has made a difference to our life. Boston has given me something to focus on when I’ve been feeling pretty down. So, he’s been great.”

Diane’s Hopes for the Future

“It’s a really good question. My greatest fear is that the cancer will come back. It’s something I live with on a daily basis. It never goes away, and I think that that is not an uncommon situation for cancer sufferers of any persuasion. The fear that you could be living well and feeling healthy at one minute, and then the next day you might get devastating news that the cancer has returned.”

“With my type of cancer that is a very real prospect in the first five years after diagnosis, and I’ve come to face that and accept that. And so, what I do is not dwell on that. I focus on the positives in my life. I have a wonderful family, a husband, a daughter, a dog, my extended family. I’m passionate about my work. I see hope and beauty in the small things, all the birds that I hear in the morning, I get woken up by them every morning before my alarm and I often just use it as a time of meditation where I can just listen to nature.”

“Nature bathing is a thing I have discovered throughout this process and it’s something I talk to my acupuncturist about all the time. I like doing Tai Chi exercise and just reveling in the small pleasures of being alive.”

“So, my hope for the future is that there will be further positive developments in terms of breast cancer treatments, and I really hope that they will make a practical difference, not just to me, but to other sufferers of this dreadful disease because it has so much potential to devastate lives.”

“And if we can get to a point where treatment is able to provide more hope, particularly for the rarer cancers and the cancers that are more aggressive, then I think that will be a good thing. So, I hope that I get to see my daughter finish high school, graduate from university, make a life for herself. I hope to retire with my husband down the south coast on a little plot of land with a tiny house. I hope to spend more time with my extended family.”

“My brother was recently diagnosed with prostate cancer and it does make me wonder about what’s going on in my family. But I hope that he recovers just as well as I have. And I just hope to live a happy, fulfilling and very, very long life.”

GIVE TO RESEARCH HELPING WOMEN LIKE MADELAINE

Latest Articles

the village effect: why community matters during breast cancer treatment
routine, resilience and research: one mum’s cancer story
split-banner-image

PRACTICE CHANGING CLINICAL TRIALS – PROFESSOR ALAN COATES AM

We spoke with one of our founders, Professor Alan Coates AM, about the ANZ-8101 and BIG 1-98 clinical trials, which were practice changing research and still have relevance today.

The Need for a Clinical Trials Group in the Late 1970’s

“At the time, all sorts of people had individual ideas about how to treat a patient with cancer, but there wasn’t a lot of evidence about which was a better way to go. An individual experience of two or three cases often changed a treating doctor’s opinion.”

“That’s not scientific, and the trouble is that you get different answers for different smaller experiences. The way to get around that is to do proper, clinical trials, which compare policies that are, that give you an answer, as to how you apply them next.”

“And so, by the time I got back from training overseas in the late 1970s, there were quite a number of people who had experience of doing clinical trials, in various parts of the world. UK, United States, particularly, and we’re setting up to do them here. The breast cancer group was the first organized group to do trials in any particular cancer in this country, with a possible exception of the pediatricians who’d done a few things in childhood leukemia, a few years earlier.”

Listen to the Podcast

Listen to our conversation with Professor Alan Coates AM as he discusses the ANZ-8101 and BIG 1-98 clinical trials, which were practice changing research and still have relevance today.

The Introduction of ANZ-8101

“You know, ANZ-8101 was an important trial. It was a successful trial that the group ran, but it wasn’t the first trial the group ran. And to put it into context, our first generation of trials compared policies in treating women with metastatic breast cancer.”

“Should they start with a hormone treatment? Should they start straight into chemotherapy? Or is it better to use both together? And we’ve got a clear answer from that first generation of trials, ANZ-7802 and ANZ-7801, that starting with endocrine treatment was just as good and put off the day when you had to give what was then very unpleasant chemotherapy.

“ANZ-8101 was a separate trial for the woman who had already required chemotherapy and was asking questions, again, trying to make life easier for women because in those days, the side effects of chemotherapy were even worse than they are now.”

“We didn’t have the ability to control, particularly nausea and vomiting, which was a major problem with all of the drugs we used and particularly some of the newer ones we were beginning to use in the 1980s.”

“So, ANZ-8101 compared different policies of using chemotherapy, and then asked questions about ‘can you give the patient a bit of a break and then go back to treatment only when you need to.’ That was a great idea. It sounded good. It worked in lymphomas and other types of cancer. It didn’t work in breast cancer, but we needed a trial to find that out, and the trial asked the question, do we start and keep going, or do we start and then give three cycles, stop and wait, and only treat if we need to.”

“The bottom line was that both from the control of the tumour, response of the treatment, how long the patient lived, and also from the point of view of the patient’s own symptoms, it was better to keep going. And the reason we know that is that this is the first trial in which patients gave their own assessment of outcomes.”

“That is what we now call patient reported outcomes or quality of life measures, which were incorporated into ANZ-8101 for the first time in ancient clinical trials in Australia. We used techniques that had been developed, particularly in the UK and by a visiting scientist from Canada who was on sabbatical, in Sydney.”

“But we used things that were simple and could be applied to hundreds of women in busy clinics and get a real measure of what those women thought about the quality of life during treatment, and the answer was very clear that in this particular comparison, the quality of life of patients who continued treatment, continued to improve. Whereas when we stopped treatment, tried to give the patient a break, quality of life deteriorated.

“And so, the idea of giving a treatment holiday in breast cancer didn’t work. And we had not only the objective measures of response rates and indeed eventually survival, but also the patient’s views of what made them feel better. And that was, of course, critically important because it was with their wellbeing in mind that the whole trial was designed.”

Improving Chemotherapy and Existing Treatments

“We needed to make the best use of the available chemotherapies, and in those days, there weren’t a lot of drugs available to choose from. One of the newer drugs was a drug called Doxorubicin or Adriamycin, and it was touted as a real improvement.”

“In fact, we used it and we used the older combination of three drugs with some cortisone drugs as well, and we compared those, one or the other, in the trial as well as the policy of stopping or continuing. It turned out that the distinction between the two types of chemotherapy wasn’t important, but the distinction of keeping going was important in terms of patient outcomes.”

The Development of the BIG 1-98 Clinical Trial

“Okay, so in BIG 1-98, we are moving in two important different ways. One, we’re talking about patients with early breast cancer that it has not yet come back. And two, because we need very large, much larger numbers to get answers in this group, we had to offer an international collaboration.”

“All of these treatments are in the endocrine treatment phase, the hormone type treatments. The mainstay that the established drug was a drug called Tamoxifen, which is undoubtedly the best drug I saw in all the years I was practicing. It made a fundamental difference to women with breast cancer.”

“A new class of drugs had come along, which was also designed to reduce the impact of endocrine treatment and endocrine agents on the tumour. That is, some tumours, most of them the tumour is driven to some extent by, estrogen in the woman’s body.”

“If you can turn that off with aromatase inhibitors or block its action with Tamoxifen, then many of the tumours will respond, and the use of those same drugs early after surgery for breast cancer, it was hoped, was going to reduce the chances of the tumour coming back, and in fact both of those work.”

“When we were starting BIG 1-98, we were trying to work out where the new drugs fitted into the sequence, and whether they should be used upfront or only if an older treatment such as Tamoxifen had failed.”

“We took a trial design that has been started by a drug company as a two-arm study comparing Tamoxifen with an aromatase inhibitor, and we designed it instead to answer academically important questions, including the sequence of starting with one and switching to the other, or starting with one and keeping it going for the whole of the treatment, which was a five-year treatment in those days.”

“So BIG 1-98 had four arms by the time we were running it and that was continuous aromatase inhibitor, a drug called Letrozole, continuous Tamoxifen, we’ll start with Tamoxifen and switch after two to three years to Letrozole or start with Letrozole and switch to Tamoxifen.”

“All of those arm’s work. They all reduce the chance of the tumour coming back on average across all patients. The arms that included Letrozole did slightly better, but what we found out by the analysis of all the patients taking part was that that benefit didn’t apply uniformly to all women.”

“Women at average or less risk did just as well with Tamoxifen alone. The sequence of starting with Tamoxifen and switching, which was being used in another trial at the same time, in the UK, was as good for most patients, except for the very high-risk ones where it was better to start with the newer drug.”

“So, for many of the patients, the sequences either way round were just as good as starting entirely with the new drug. That’s important because if a woman finds that the side effects of one or other of these drugs is unacceptable and intolerable, then this trial gives you solid evidence that it’s safe to switch to the other sort. And the women, they prefer that. So that’s a piece of knowledge that is valuable in the clinic for people who can’t tolerate one or other of the drugs.”

BCT’s Involvement In Other More Recent Major Breakthroughs

“I think the next important group was to look at the premenopausal adjuvant studies. This is the group of studies called SOFT and TEXT, that Prue Francis has led for our group. And that’s asking the same sort of questions about the treatment of women before the menopause. Tamoxifen again was the mainstay of treatment. Is it better to use one of these new drugs?”

“The problem is that you can’t just give a premenopausal woman Letrozole. It would be swamped by the estrogen that her body makes. And so, as part of that treatment, you have to turn off estrogen production with another sort of drug.”

So, there’s an LHRH agonist drug that’s used triptorelin or gooseling, which turns off the body’s ability to make estrogen. And then you can use a drug like letrozole. Stopping the estrogen production in and of itself was another possibility. So, some of the arms that were used in these studies were Tamoxifen alone, Tamoxifen plus the blocker, or the blocker making it possible to use Letrozole.”

“And again, it depends on the degree of risk, and Dr Francis will tell you more about the details of this, but it seems to me the complicated treatments, the ones that involve stopping estrogen production and then using, a drug like Letrozole are beneficial, but they’re beneficial, particularly for women at higher risk. Whereas for women at low risk, a simple treatment like Tamoxifen might be quite adequate.”

Looking Towards the Future of Breast Cancer Research

“The game is changing. When we did trials like BIG 1-98, or ANZ-8101, almost all the patients who came to your clinic would be eligible for that question because it, as far as we knew, the question applied to all of them. Nowadays we are finding out so much more about the subgroups within breast cancer, that the group of patients for whom any treatment question applies is smaller and smaller.”

“So, it’s getting harder to find questions that have enough patients to be answered reliably. And that’s requiring a great deal of collaboration internationally to get the numbers required for the statistics to work, on groups of patients that are increasingly defined by molecular subtypes that we now understand in breast cancer.”

“I think that the clinical research gives us reliable information so we can advise patients not on the basis of whim and personal experience, but on solid science. And that’s what the last 50-years of clinical trials have contributed to the wellbeing of the next woman who comes through the door.”

Support Us

Help us to change lives through breast cancer clinical trials research

Latest Articles

the village effect: why community matters during breast cancer treatment
routine, resilience and research: one mum’s cancer story
split-banner-image

DEVELOPING NEW TREATMENTS FOR INVASIVE LOBULAR CARCINOMA

As part of a Clinical Fellowship project with Breast Cancer Trials, Dr Anna Sokolova, is examining a new treatment approach directed towards Invasive Lobular Carcinoma.

What is Invasive Lobular Carcinoma?

Invasive Lobular Carcinoma (ILC) is a breast cancer that begins in the milk glands of the breast and has spread beyond the lobules, potentially spreading to the lymph nodes and other parts of the body.

“So Invasive Lobular Carcinoma is a special breast cancer subtype. It’s the second most common breast cancer subtype, and it accounts for around 10 to 15% of all breast cancer cases. So that is around 2,400 new breast cancer diagnoses per year in Australia.”

“Invasive Lobular Carcinoma is also unique in terms of its pathology and clinical behaviour. And patients with Invasive Lobular Carcinoma show worse long term prognostic outcomes compared to patients who are diagnosed with the most common breast cancer subtype.”

Listen to the Podcast

Listen to our conversation with Dr Anna Sokolova, who is examining a new treatment approach directed towards Invasive Lobular Carcinoma. 

What are the Current Treatments for this Type of Breast Cancer?

“So, in terms of treatment, patients with Invasive Lobular Carcinoma do not have a specific targeted treatment strategy that is unique to their clinical needs. So, patients with Invasive Lobular Carcinoma are treated in the same way as other breast cancer patients using standard treatment protocols that include surgery, radiotherapy, and chemotherapy.”

“So, there is emerging evidence that a protein called ROS1 is an important target in Invasive Lobular breast cancer. And there are two recently established clinical trials in Europe that are assessing the efficacy of ROS1, targeted treatment in managing patients with Invasive Lobular breast cancer. So, my clinical fellowship is investigating the expression of the ROS1 protein in these tumours and trying to determine whether ROS1 is a useful biomarker that can help to predict which patients will respond to this targeted treatment.”

Is there Potential for a Clinical Trial down the Track?

“So lobular breast cancer patients are not well represented in clinical trials, and they do not have specific treatment options available. So, there is an unmet need for this patient group to have trials that are specifically devoted to their disease process.”

“There are two clinical trials that are currently being established, in Europe, and there’s potential to expand these clinical trials to Australian and New Zealand patients in the future.”

“I think pathology is extremely important in breast cancer trials research. It is a multidisciplinary approach, but pathology has a lot to offer in terms of identifying biomarkers, assessing tissue samples, and driving the laboratory aspect of clinical research, and giving a different perspective on clinical outcomes.”

Dr Sokolova’s Hope for the Future

“I hope that this research will identify a clinically useful biomarker that will help to identify patients who may benefit from new targeted treatment approaches in Invasive Lobular breast cancer. So, there are two early clinical trials that have been established overseas looking at ROS1 targeted treatment in these patients.”

“Depending on the results of these trials, they may be offered overseas to other countries, and that may include Australian and New Zealand patients.”

Support Us

Help us to change lives through breast cancer clinical trials research

Latest Articles

the village effect: why community matters during breast cancer treatment
routine, resilience and research: one mum’s cancer story
split-banner-image

EASING THE FEAR OF BREAST CANCER RECURRENCE

As part of a Clinical Fellowship project with Breast Cancer Trials, psychologist and psycho-oncology researcher, Michelle Sinclair, is examining the role that breast cancer treatment plays in the development of fear of recurrence and the impact that this fear has on a patient’s quality of life.

What is a Fear of Recurrence?

The fear of breast cancer coming back is a very real and common concern for many people diagnosed with breast cancer.

“So, after a breast cancer diagnosis, it’s really understandable that women will have a concern about the cancer returning or progressing. So, a fear of cancer recurrence is essentially a fear about cancer recurring or coming back in the breast or in another part of the body.”

“It really entails a worry or concern, and it can range from a normal level of concern to quite significant, persistent thoughts and anxiety. So, women tell us that managing a fear of cancer recurrence is one of their most significant unmet needs and  around 40-70% of those women, the concern is so severe that it impacts their daily quality of life.”

“So, this is a really important area of research for us to better understand.”

Listen to the Podcast

Listen to our conversation with Ms Michelle Sinclair as she discusses the role that breast cancer treatment plays in the development of fear of recurrence and the impact that this fear has on a patient’s quality of life.

What are the Side Effects of Having a Fear of Recurrence?

“Fear of recurrence ranges from no concern at all, where the thought doesn’t enter the woman’s mind, to quite severe debilitating anxiety. And for women who have the more severe fear cancer recurrence, they describe that they’re unable to plan for the future, that their enjoyment is really impacted, they’re hypervigilant to signs of recurrence in their bodies. And so, it really can impact their quality of life in a significant way.”

“So, this is really important, as fear of cancer recurrence is unlikely to reduce without interventional treatment, so it can last for years into survivorship.”

“I think firstly it’s really important to establish that having thoughts about fear of cancer recurrence is not an overreaction, it’s not an irrational fear. So, the threat is real.”

How can People with this Fear be Supported?

“When this fear and this concern impacts all aspects of someone’s life and is persistent and really distressing for them, and they can’t plan holidays for the future, and they really are noticing that they are concerned about any change in their body for a sign of recurrence, that’s when intervention and treatment can really assist these women to live with a fear of cancer recurrence in a better way and to reduce the impacts that it has on their lives.”

“So, treatments are quite effective and there’s a broad range of treatments that are available, the most common of which is cognitive behavioral therapy, which is an umbrella term to refer to several different therapies that really build coping strategies and skills for women. They have been shown to reduce the frequency and intensity of fear of cancer recurrence thoughts, and really improve quality of life into survivorship for breast cancer patients.”

“We actually don’t know enough about how different cancer treatment pathways impact fear of cancer recurrence or psychosocial outcomes. And so, this is an important step so that we can have a better idea of what may contribute to more severe levels of a fear of cancer recurrence.”

What does your Research Project Involve?

“We need to be aware of different treatments and how they impact the levels of fear so that we can be more attuned to those patients who might be more vulnerable and who we intervene with or provide better support for sooner.”

“So, the project I’m working on is looking at three treatment pathways, with early breast cancer that have been recommended. We’re then comparing the level of fear of cancer recurrence between these women to better understand how the fear of cancer recurrence may be influenced by their recommended treatment pathway.”

Why are you Investigating Data of the PROSPECT Trial and De-escalation of Treatment?

“So, there’s a growing amount of evidence that de-escalation is an appropriate treatment pathway for some women with early breast cancer, and therefore this might become a more common treatment pathway. But we don’t understand how de-escalation can impact psychological wellbeing or fear of cancer recurrence in these women.”

“And so that’s really important for us to understand if this is to become a usual care pathway or a more common form of treatment. So, we want to understand if de-escalation is associated with increased fear of cancer recurrence. So, we’re asking the question, ‘does receiving less treatment increase the amount of fear of cancer recurrence women have?”

“PROSPECT involves screening women with early breast cancer via MRI to assess suitability for de-escalation. And we’ll be exploring levels of fear of cancer recurrence in the women on the PROSPECT trial, but also in another sample of women who had usual care, so they weren’t on a clinical trial.”

“And this way we’re able to compare the level of fear of cancer recurrence across different treatment pathways and better understand how their treatment may have impacted their quality of life and their levels of fear.”

Is this a New Area of Research?

“Our understanding of fear of cancer recurrence in breast cancer patients is quite well established, but as de-escalation of radiation therapy as a potential treatment pathway is a relatively new area, understanding how fear of cancer occurrence in, women who undergo de-escalation is definitely a new area and we don’t know enough about it at all.”

Support Us

Help us to change lives through breast cancer clinical trials research

Latest Articles

the village effect: why community matters during breast cancer treatment
routine, resilience and research: one mum’s cancer story
split-banner-image

CDK4/6 INHIBITORS – MAKING THE MOST OF A GOOD THING

CDK4/6 inhibitors are a class of drugs that are being given to patients in order to treat certain types of breast cancer and have been proven to help stop the division of cancer cells.

What are CDK4/6 Inhibitors?

CDK4/6 inhibitors are a class of drugs that are being given to patients in order to treat certain types of breast cancer and have been proven to help stop the division of cancer cells.

Breast Cancer Trials has been directly involved with research into CDK4/6 inhibitors since they were introduced in 2015. With Palbociclib being the first drug. These trials include Penelope B, PALLAS, PATINA, and the Paloma 2 trial which led to the registration and PBS listing of Palbociclib.

Dr Shom Goel is a clinician-scientist at the University of Melbourne and Peter MacCallum Cancer Centre, with a strong interest in translational breast cancer research. He was a guest speaker at the 2022 Breast Cancer Trials Annual Scientific Meeting. And we asked Dr Goel to explain his research into CDK4/6 inhibitors and where research is going in the future.

“CDK4/6 is a long-winded name, but essentially these are tablets that people can take at home that have been shown to help stop cancer cells from dividing. That’s the primary way that they work.”

“And at the moment we have found that if we combine those CDK4/6 inhibitors with hormonal therapy, this is for patients who have breast cancer that’s called hormone receptor positive (HR+), it significantly improves outcomes for patients compared to giving hormone therapy alone.”

“So, in that subgroup of patients, these drugs have really been a game changer. At the moment we use them mainly for patients with what we call advanced hormone receptor positive breast cancer. That means cancer that spread to other parts of the body. But we are looking to see whether they could also be useful in early-stage disease.”

Listen to the Podcast

Listen to our conversation with Dr Shom Goel as he discusses the CDK 4/6 Inhibitors.

‘Making the Most of a Good Thing’

“So, my presentation is called ‘CDK4/6 Inhibitors – Making the Most of a Good Thing’. I’m talking about that topic because that is what my laboratory research is all about. I say ‘a good thing’ because I think these drugs really have dramatically improved outcomes for many women with breast cancer.”

“And I say, ‘making the most of’ because I think there’s still a lot more we can do to bring these treatments to more women and see better outcomes for patients in different settings, or even with different subtypes of breast cancer.”

“What’s really interesting about these drugs is that they work by stopping cancer cells from dividing. But our research has also shown that they can boost the immune system’s attack against the cancer. And we think that’s why they might be particularly interesting drugs for patients with triple-negative disease.”

Where is Research Going in the Future with CDK4/6 Inhibitors?

“It’s a really exciting time for this class of drugs. They’re clearly here to stay which is great. And so now it’s upon us as researchers to find out how we can use them better. I’d say the first thing that’s coming, is the introduction of these drugs in what we call the early-stage breast cancer setting. So, this is not only about treating patients with advanced disease but now using these drugs to try and prevent breast cancer recurrence and increase people’s chances of a long-term cure.”

“And the second thing that I think is really exciting, are attempts to bring these drugs to patients with other subtypes of breast cancer. So, we talk about another subtype called HER2-positive breast cancer.”

“There have already been clinical trials looking at CDK4/6 inhibitors in that patient group, some of which Breast Cancer Trials was heavily involved with. And we’re just waiting to see if those trials look good, and we’re optimistic.”

“There are even trials which I’m involved with seeing whether we might be able to use these drugs for patients with what’s called triple-negative breast cancer.”

Support Us

Help us to change lives through breast cancer clinical trials research

Latest Articles

the village effect: why community matters during breast cancer treatment
routine, resilience and research: one mum’s cancer story